Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Aravive, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age 18 years or older
Histologically or cytologically confirmed pancreatic adenocarcinoma. Must have locally advanced, recurrent, or metastatic disease ineligible for curative intent treatment(s) and eligible for first line systemic treatment.
Must have radiologic imaging with a computed tomography (CT) scan or magnetic resonance imaging (MRI) within 22 days of study entry
Must have at least one measurable lesion according to RECIST 1.1
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
Adequate gastrointestinal (GI), bone marrow, liver and kidney function
Life expectancy minimum of \> 12 weeks
Adequate recovery from surgery to Grade 1 or baseline with at least 28 days from time of major surgery
You may not be if
Received last dose of chemotherapy (neoadjuvant or adjuvant), surgery, or radiation treatment with curative intent within 6 months prior to study entry
Islet-cell neoplasms
Prior malignancy within the past 3 years except adequately treated basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the prostate, cervix, breast or melanoma
Symptomatic uncontrolled central nervous system (CNS) metastasis or brain metastases unless adequately treated and controlled
Evidence of clinically significant third spacing (e.g. pleural effusion, ascites, anasarca, etc.) within 28 days prior to study entry
Serious active infection requiring IV antibiotics and/or hospitalization at study entry
Active human immune deficiency (HIV) syndrome, hepatitis B, hepatitis C, or other active viral illness
